ir/
68 pages · Updated July 26, 2026
Pages
- June 29, 2026 - EX-99.1 - 8-K: Current report | Evommune, Inc. (EVMN)
- July 16, 2026 - JOINT FILING AGREEMENT - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)
- July 16, 2026 - SCHEDULE 13G: Statement of Beneficial Ownership by Certain Investors | Evommune, Inc. (EVMN)
- June 24, 2026 - Patel Jeegar Pravinkumar - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- June 29, 2026 - 8-K: Current report | Evommune, Inc. (EVMN)
- June 29, 2026 - 424B3: Prospectus [Rule 424(b)(3)] | Evommune, Inc. (EVMN)
- June 24, 2026 - Drew Janice Suzann - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- July 8, 2026 - Kirsch Arthur S - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- July 10, 2026 - Carver Kyle - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- June 24, 2026 - Pena Luis C. - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- June 3, 2026 - Mcgraw Benjamin F Iii - 4: Statement of changes in beneficial ownership of securities | Evommune, Inc. (EVMN)
- June 22, 2026 - 144: Report of proposed sale of securities | Evommune, Inc. (EVMN)
- rss
- March 5, 2026 - EX-4.3 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- March 5, 2026 - EX-97 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress :: Evommune, Inc. (EVMN)
- March 5, 2026 - EX-19.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- December 11, 2025 - EX-31.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- March 5, 2026 - EX-32.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- March 5, 2026 - EX-31.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- March 5, 2026 - EX-31.2 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- December 11, 2025 - EX-32.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- March 5, 2026 - EX-23.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- May 7, 2026 - EX-31.2 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- May 7, 2026 - EX-32.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- Accessibility Request Form :: Evommune, Inc. (EVMN)
- evommune-announces-positive-top-line-datafrom-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis.html
- March 5, 2026 - EX-21.1 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Evommune, Inc. (EVMN)
- Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update :: Evommune, Inc. (EVMN)
- Evommune Announces Pricing of its Initial Public Offering :: Evommune, Inc. (EVMN)
- Evommune Announces Commencement of Initial Public Offering :: Evommune, Inc. (EVMN)
- Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares :: Evommune, Inc. (EVMN)
- Evommune Announces $125 Million Private Placement :: Evommune, Inc. (EVMN)
- May 7, 2026 - EX-31.1 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- December 11, 2025 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- Disclaimer :: Evommune, Inc. (EVMN)
- Privacy Policy :: Evommune, Inc. (EVMN)
- Past Events :: Evommune, Inc. (EVMN)
- Evommune EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis :: Evommune, Inc. (EVMN)
- KOL Webinar Highlighting Role of MRGPRX2 in Migraine :: Evommune, Inc. (EVMN)
- May 7, 2026 - 10-Q: Quarterly report [Sections 13 or 15(d)] | Evommune, Inc. (EVMN)
- financial-information
- 2026 Annual Meeting of Stockholders :: Evommune, Inc. (EVMN)
- news-events
- rss-news-feed
- Accessibility Statement :: Evommune, Inc. (EVMN)
- Analyst Coverage :: Evommune, Inc. (EVMN)
- rss
- Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis :: Evommune, Inc. (EVMN)
- Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights :: Evommune, Inc. (EVMN)
- rss
- Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria :: Evommune, Inc. (EVMN)
- Historical Data :: Evommune, Inc. (EVMN)
- SEC Filings :: Evommune, Inc. (EVMN)
- Board Committees :: Evommune, Inc. (EVMN)
- Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights :: Evommune, Inc. (EVMN)
- Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine :: Evommune, Inc. (EVMN)
- Financial Results :: Evommune, Inc. (EVMN)
- Corporate Governance :: Evommune, Inc. (EVMN)
- Governance Documents :: Evommune, Inc. (EVMN)
- Press Releases :: Evommune, Inc. (EVMN)
- Quote & Chart :: Evommune, Inc. (EVMN)
- IR Calendar :: Evommune, Inc. (EVMN)
- Contacts :: Evommune, Inc. (EVMN)
- FAQ :: Evommune, Inc. (EVMN)
- Email Alerts :: Evommune, Inc. (EVMN)
- Presentations :: Evommune, Inc. (EVMN)
- Company Info :: Evommune, Inc. (EVMN)